Trust & Proof: RINVOQ (AbbVie Inc.) – Signal Evidence & AI Readability

{
    "@context": "http://schema.org",
    "@type": "MedicalWebPage",
    "audience": "https://health-lifesci.schema.org/Patient",
    "specialty": "http://health-lifesci.schema.org/Rheumatology",
    "reviewedBy": "AbbVie Inc.",
    "dateModified": "2022-10-21",
    "headline": "RINVOQ® (upadacitinib) Treatment for RA, PsA, AD, AS, nr-axSpA and UC",
    "description": "Learn about RINVOQ® (upadacitinib), a once-daily pill that helps tame symptoms in six conditions. See full Prescribing & Safety Info, and BOXED WARNING.",
    "url": "https://www.rinvoq.com/",
    "primaryImageOfPage": [
        {
            "@type": "ImageObject",
            "name": "Rinvoq Relief is Possible: RINVOQ is a once-daily pill that helps tame symptoms in 6 conditions",
            "url": "https://www.rinvoq.com/content/dam/rinvoq/images/homepage/rinvoq-relief-is-here_1200-1800.png"
        }
    ],
    "potentialaction": {
        "0": {
            "@type": "ViewAction",
            "name": "Eczema",
            "url": "https://www.rinvoq.com/atopic-dermatitis"
        },
        "1": {
            "@type": "ViewAction",
            "name": "Rheumatoid Arthritis",
            "url": "https://www.rinvoq.com/rheumatoid-arthritis"
        },
        "2": {
            "@type": "ViewAction",
            "name": "Psoriatic Arthritis",
            "url": "https://www.rinvoq.com/psoriatic-arthritis"
        },
        "3": {
            "@type": "ViewAction",
            "name": "Ankylosing Spondylitis",
            "url": "https://www.rinvoq.com/ankylosing-spondylitis"
        },
        "4": {
            "@type": "ViewAction",
            "name": "Non-radiographic Axial Spondyloarthritis",
            "url": "https://www.rinvoq.com/non-radiographic-axial-spondyloarthritis"
        },
        "_items_truncated": true
    },
    "image": [
        {
            "@type": "ImageObject",
            "name": "RINVOQ® Complete logo",
            "contentUrl": "https://www.rinvoq.com/content/dam/rinvoq/images/homepage/rinvoq-complete-logo-white-brushstroke-desktop-r9.png"
        }
    ],
    "mainEntity": [
        {
            "@type": "Question",
            "text": "What is the most important information I should know about RINVOQ?",
            "acceptedAnswer": {
                "@type": "Answer",
                "text": [
                    "RINVOQ may cause serious side effects, including: Serious infections. RINVOQ can lower your ability to fight infections. Serious infections have happened while taking RINVOQ, including tuberculosis (TB) and infections caused by bacteria, fungi, or viruses that can spread throughout the body. Some people have died from these infections. Your healthcare provider (HCP) should test you for TB before starting RINVOQ and check you closely for signs and symptoms of TB during treatment with RINVOQ. You "
                ]
            }
        },
        {
            "@type": "Question",
            "text": "What should I tell my HCP before taking RINVOQ?",
            "acceptedAnswer": {
                "@type": "Answer",
                "text": [
                    "Tell your HCP if you: Are being treated for an infection, have an infection that won’t go away or keeps coming back, or have symptoms of an infection, such as: - Fever, sweating, or chills - Shortness of breath - Warm, red, or painful skin or sores on your body - Muscle aches - Feeling tired - Blood in phlegm - Diarrhea or stomach pain - Cough - Weight loss - Burning when urinating or urinating more often than normal. Have TB or have been in close contact with someone with TB. Are a current or p"
                ]
            }
        },
        {
            "@type": "Question",
            "text": "What should I tell my HCP after starting RINVOQ?",
            "acceptedAnswer": {
                "@type": "Answer",
                "text": [
                    "Tell your HCP right away if you have any symptoms of an infection. RINVOQ can make you more likely to get infections or make any infections you have worse. Get emergency help right away if you have any symptoms of a heart attack or stroke while taking RINVOQ, including: - Discomfort in the center of your chest that lasts for more than a few minutes or that goes away and comes back - Severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw - Pain or discomfort in your ar"
                ]
            }
        },
        {
            "@type": "Question",
            "text": "What are the common side effects of RINVOQ?",
            "acceptedAnswer": {
                "@type": "Answer",
                "text": [
                    "These include upper respiratory tract infections (common cold, sinus infections), shingles (herpes zoster), herpes simplex virus infections, including cold sores, bronchitis, nausea, cough, fever, acne, headache, increased blood levels of creatine phosphokinase, allergic reactions, inflammation of hair follicles, stomach-area (abdominal) pain, increased weight, flu, tiredness, low white blood cell count (neutropenia), muscle pain, and flu-like illness. A separation or tear to the lining of the b"
                ]
            }
        },
        {
            "@type": "Question",
            "text": "How should I take RINVOQ?",
            "acceptedAnswer": {
                "@type": "Answer",
                "text": [
                    "RINVOQ is taken once a day with or without food. Do not split, break, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it. RINVOQ is available in 15 mg and 30 mg extended-release tablets."
                ]
            }
        }
    ],
    "about": [
        {
            "@type": "Drug",
            "name": "RINVOQ",
            "nonProprietaryName": "upadacitinib",
            "image": {
                "@type": "ImageObject",
                "name": "Rinvoq (upadacitinib) Logo",
                "contentUrl": "https://www.rinvoq.com/content/dam/rinvoq/images/common/rinvoq-logo-white-desktop-r9.png"
            },
            "description": "RINVOQ™ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. ",
            "prescribingInfo": "https://www.rxabbvie.com/pdf/rinvoq_pi.pdf",
            "warning": "Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving RINVOQ. If a serious infection develops, interrupt RINVOQ until the infection is controlled. Prior to starting RINVOQ, perform a test for latent tuberculosis; if it is positive, start treatment for tuberculosis prior to starting RINVOQ. Monitor all patients for active tuberculosis during treatment, even if th",
            "pregnancyWarning": "The limited human data on use of RINVOQ in pregnant women are not sufficient to evaluate a drug-associated risk for major birth defects or  iscarriage. Based on animal studies, upadacitinib has the potential to adversely affect a developing fetus. ",
            "breastfeedingWarning": "There are no data on the presence of upadacitinib in human milk, the effects on the breastfed infant, or the effects on milk production. Available pharmacodynamic/toxicological data in animals have shown excretion of upadacitinib in milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. Because of the potential for serious adverse reactions in the breastfed infant, advise patients that breastfeeding is not recommended during treatment with upadacit",
            "prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
            "dosageForm": [
                "Tablet"
            ],
            "administrationRoute": "oral",
            "doseSchedule": {
                "@type": "DoseSchedule",
                "frequency": "daily",
                "doseValue": "15",
                "doseUnit": "mg"
            },
            "manufacturer": {
                "@type": "Corporation",
                "name": "Abbvie"
            }
        }
    ],
    "_truncated": true,
    "_original_size": 11731
}

{
    "@context": "http://schema.org",
    "@type": "MedicalWebPage",
    "audience": "https://health-lifesci.schema.org/Patient",
    "specialty": "http://health-lifesci.schema.org/Rheumatology",
    "reviewedBy": "AbbVie Inc.",
    "dateModified": "2022-04-12",
    "headline": "RINVOQ® (upadacitinib) Cost",
    "description": "Find the cost for RINVOQ based on your health insurance or other financial options. See full Prescribing & Safety Information and BOXED WARNING.",
    "url": "https://www.rinvoq.com/cost",
    "primaryImageOfPage": [
        {
            "@type": "ImageObject",
            "name": "With RINVOQ Complete Savings Card, you could pay $5 a month",
            "url": "https://www.rinvoq.com/content/dam/rinvoq/images/homepage/temp-cost-and-savings/savings-card_r13_desktop.png"
        }
    ],
    "potentialaction": [
        {
            "@type": "ViewAction",
            "name": "Learn about the card",
            "description": "You could pay $5 a month with the RINVOQ Complete Savings Card",
            "url": "https://www.rinvoq.com/resources/save-on-rinvoq-costs"
        },
        {
            "@type": "ViewAction",
            "name": "Uninsured or if you cannot afford your medication",
            "description": "If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more.",
            "url": "https://www.abbvie.com/patients/patient-assistance.html?utm_source=myAbbVie-Assist-URL"
        },
        {
            "@type": "ViewAction",
            "name": "myAbbVie Assist",
            "url": "https://www.abbvie.com/patients/patient-assistance.html?utm_source=myAbbVie-Assist-URL"
        }
    ],
    "about": [
        {
            "@type": "Drug",
            "name": "RINVOQ",
            "nonProprietaryName": "upadacitinib",
            "image": {
                "@type": "ImageObject",
                "name": "Rinvoq (upadacitinib) Logo",
                "contentUrl": "https://www.rinvoq.com/content/dam/rinvoq/images/common/rinvoq-logo-white-desktop-r9.png"
            },
            "description": "RINVOQ™ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. ",
            "prescribingInfo": "https://www.rxabbvie.com/pdf/rinvoq_pi.pdf",
            "warning": "Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving RINVOQ. If a serious infection develops, interrupt RINVOQ until the infection is controlled. Prior to starting RINVOQ, perform a test for latent tuberculosis; if it is positive, start treatment for tuberculosis prior to starting RINVOQ. Monitor all patients for active tuberculosis during treatment, even if the initial latent tuberculosis test is negative. Lymphoma and other malignancies have been observed in patients treated with RINVOQ. Thrombosis, including deep vein thrombosis, pulmonary embolism, and arterial thrombosis, have occurred in patients treated with Janus kinase inhibitors used to treat inflammatory conditions.",
            "pregnancyWarning": "The limited human data on use of RINVOQ in pregnant women are not sufficient to evaluate a drug-associated risk for major birth defects or  iscarriage. Based on animal studies, upadacitinib has the potential to adversely affect a developing fetus. ",
            "breastfeedingWarning": "There are no data on the presence of upadacitinib in human milk, the effects on the breastfed infant, or the effects on milk production. Available pharmacodynamic/toxicological data in animals have shown excretion of upadacitinib in milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. Because of the potential for serious adverse reactions in the breastfed infant, advise patients that breastfeeding is not recommended during treatment with upadacitinib, and for 6 days (approximately 10 half-lives) after the last dose. ",
            "prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
            "dosageForm": [
                "Tablet"
            ],
            "administrationRoute": "oral",
            "doseSchedule": {
                "@type": "DoseSchedule",
                "frequency": "daily",
                "doseValue": "15",
                "doseUnit": "mg"
            },
            "manufacturer": {
                "@type": "Corporation",
                "name": "Abbvie"
            }
        }
    ]
}

{
    "@context": "http://schema.org",
    "@type": "MedicalWebPage",
    "audience": "https://health-lifesci.schema.org/Patient",
    "specialty": "http://health-lifesci.schema.org/Rheumatologic",
    "reviewedBy": "AbbVie Inc.",
    "dateModified": "2022-02-16",
    "headline": "Sign Up for More Information | RINVOQ® (upadacitinib)",
    "description": "Sign up for information, resources, and support for people who are taking, or considering, RINVOQ. See Important Safety Information, including BOXED WARNING.",
    "url": "https://www.rinvoq.com/sign-up",
    "about": [
        {
            "@type": "Drug",
            "name": "RINVOQ",
            "nonProprietaryName": "upadacitinib",
            "image": {
                "@type": "ImageObject",
                "name": "Rinvoq (upadacitinib) Logo",
                "contentUrl": "https://www.rinvoq.com/content/dam/rinvoq/images/common/rinvoq-logo-white-desktop-r9.png"
            },
            "description": "RINVOQ™ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. ",
            "prescribingInfo": "https://www.rxabbvie.com/pdf/rinvoq_pi.pdf",
            "warning": "Serious infections leading to hospitalization or death, including tuberculosis and bacterial, invasive fungal, viral, and other opportunistic infections, have occurred in patients receiving RINVOQ. If a serious infection develops, interrupt RINVOQ until the infection is controlled. Prior to starting RINVOQ, perform a test for latent tuberculosis; if it is positive, start treatment for tuberculosis prior to starting RINVOQ. Monitor all patients for active tuberculosis during treatment, even if the initial latent tuberculosis test is negative. Lymphoma and other malignancies have been observed in patients treated with RINVOQ. Thrombosis, including deep vein thrombosis, pulmonary embolism, and arterial thrombosis, have occurred in patients treated with Janus kinase inhibitors used to treat inflammatory conditions.",
            "pregnancyWarning": "The limited human data on use of RINVOQ in pregnant women are not sufficient to evaluate a drug-associated risk for major birth defects or  iscarriage. Based on animal studies, upadacitinib has the potential to adversely affect a developing fetus. ",
            "breastfeedingWarning": "There are no data on the presence of upadacitinib in human milk, the effects on the breastfed infant, or the effects on milk production. Available pharmacodynamic/toxicological data in animals have shown excretion of upadacitinib in milk. When a drug is present in animal milk, it is likely that the drug will be present in human milk. Because of the potential for serious adverse reactions in the breastfed infant, advise patients that breastfeeding is not recommended during treatment with upadacitinib, and for 6 days (approximately 10 half-lives) after the last dose. ",
            "prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
            "dosageForm": [
                "Tablet"
            ],
            "administrationRoute": "oral",
            "doseSchedule": {
                "@type": "DoseSchedule",
                "frequency": "daily",
                "doseValue": "15",
                "doseUnit": "mg"
            },
            "manufacturer": {
                "@type": "Corporation",
                "name": "Abbvie"
            }
        }
    ]
}